1gi6 › Citations

A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.

Katz BA, Elrod K, Luong C, Rice MJ, Mackman RL, Sprengeler PA, Spencer J, Hataye J, Janc J, Link J, Litvak J, Rai R, Rice K, Sideris S, Verner E, Young W
J Mol Biol 307 1451-86 (2001)
Related entries: 1ghv, 1ghw, 1ghx, 1ghy, 1ghz, 1gi0, 1gi1, 1gi2, 1gi3, 1gi4, 1gi5, 1gi7, 1gi8, 1gi9

Cited: 44 times
EuropePMC logo PMID: 11292354

Abstract

We describe a new serine protease inhibition motif in which binding is mediated by a cluster of very short hydrogen bonds (<2.3 A) at the active site. This protease-inhibitor binding paradigm is observed at high resolution in a large set of crystal structures of trypsin, thrombin, and urokinase-type plasminogen activator (uPA) bound with a series of small molecule inhibitors (2-(2-phenol)indoles and 2-(2-phenol)benzimidazoles). In each complex there are eight enzyme-inhibitor or enzyme-water-inhibitor hydrogen bonds at the active site, three of which are very short. These short hydrogen bonds connect a triangle of oxygen atoms comprising O(gamma)(Ser195), a water molecule co-bound in the oxyanion hole (H(2)O(oxy)), and the phenolate oxygen atom of the inhibitor (O6'). Two of the other hydrogen bonds between the inhibitor and active site of the trypsin and uPA complexes become short in the thrombin counterparts, extending the three-centered short hydrogen-bonding array into a tetrahedral array of atoms (three oxygen and one nitrogen) involved in short hydrogen bonds. In the uPA complexes, the extensive hydrogen-bonding interactions at the active site prevent the inhibitor S1 amidine from forming direct hydrogen bonds with Asp189 because the S1 site is deeper in uPA than in trypsin or thrombin. Ionization equilibria at the active site associated with inhibitor binding are probed through determination and comparison of structures over a wide range of pH (3.5 to 11.4) of thrombin complexes and of trypsin complexes in three different crystal forms. The high-pH trypsin-inhibitor structures suggest that His57 is protonated at pH values as high as 9.5. The pH-dependent inhibition of trypsin, thrombin, uPA and factor Xa by 2-(2-phenol)benzimidazole analogs in which the pK(a) of the phenol group is modulated is shown to be consistent with a binding process involving ionization of both the inhibitor and the enzyme. These data further suggest that the pK(a) of His57 of each protease in the unbound state in solution is about the same, approximately 6.8. By comparing inhibition constants (K(i) values), inhibitor solubilities, inhibitor conformational energies and corresponding structures of short and normal hydrogen bond-mediated complexes, we have estimated the contribution of the short hydrogen bond networks to inhibitor affinity ( approximately 1.7 kcal/mol). The structures and K(i) values associated with the short hydrogen-bonding motif are compared with those corresponding to an alternate, Zn(2+)-mediated inhibition motif at the active site. Structural differences among apo-enzymes, enzyme-inhibitor and enzyme-inhibitor-Zn(2+) complexes are discussed in the context of affinity determinants, selectivity development, and structure-based inhibitor design.

Articles - 1gi6 mentioned but not cited (4)

  1. Assessment of programs for ligand binding affinity prediction. Kim R, Skolnick J. J Comput Chem 29 1316-1331 (2008)
  2. A knowledge-guided strategy for improving the accuracy of scoring functions in binding affinity prediction. Cheng T, Liu Z, Wang R. BMC Bioinformatics 11 193 (2010)
  3. Path-integral method for predicting relative binding affinities of protein-ligand complexes. Mulakala C, Kaznessis YN. J Am Chem Soc 131 4521-4528 (2009)
  4. Prediction of ligand binding using an approach designed to accommodate diversity in protein-ligand interactions. Marsh L. PLoS One 6 e23215 (2011)


Reviews citing this publication (1)

  1. Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity. El Salamouni NS, Buckley BJ, Ranson M, Kelso MJ, Yu H. Biophys Rev 14 277-301 (2022)

Articles citing this publication (39)

  1. Current status of the AMOEBA polarizable force field. Ponder JW, Wu C, Ren P, Pande VS, Chodera JD, Schnieders MJ, Haque I, Mobley DL, Lambrecht DS, DiStasio RA, Head-Gordon M, Clark GN, Johnson ME, Head-Gordon T. J Phys Chem B 114 2549-2564 (2010)
  2. Ultra-large library docking for discovering new chemotypes. Lyu J, Wang S, Balius TE, Singh I, Levit A, Moroz YS, O'Meara MJ, Che T, Algaa E, Tolmachova K, Tolmachev AA, Shoichet BK, Roth BL, Irwin JJ. Nature 566 224-229 (2019)
  3. Funnel metadynamics as accurate binding free-energy method. Limongelli V, Bonomi M, Parrinello M. Proc Natl Acad Sci U S A 110 6358-6363 (2013)
  4. Calculation of protein-ligand binding free energy by using a polarizable potential. Jiao D, Golubkov PA, Darden TA, Ren P. Proc Natl Acad Sci U S A 105 6290-6295 (2008)
  5. Virtual screening using molecular simulations. Yang T, Wu JC, Yan C, Wang Y, Luo R, Gonzales MB, Dalby KN, Ren P. Proteins 79 1940-1951 (2011)
  6. Trypsin-ligand binding free energies from explicit and implicit solvent simulations with polarizable potential. Jiao D, Zhang J, Duke RE, Li G, Schnieders MJ, Ren P. J Comput Chem 30 1701-1711 (2009)
  7. Ligand binding free-energy calculations with funnel metadynamics. Raniolo S, Limongelli V. Nat Protoc 15 2837-2866 (2020)
  8. The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain. Somoza JR, Ho JD, Luong C, Ghate M, Sprengeler PA, Mortara K, Shrader WD, Sperandio D, Chan H, McGrath ME, Katz BA. Structure 11 1123-1131 (2003)
  9. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Katz BA, Sprengeler PA, Luong C, Verner E, Elrod K, Kirtley M, Janc J, Spencer JR, Breitenbucher JG, Hui H, McGee D, Allen D, Martelli A, Mackman RL. Chem Biol 8 1107-1121 (2001)
  10. Could MM-GBSA be accurate enough for calculation of absolute protein/ligand binding free energies? Mulakala C, Viswanadhan VN. J Mol Graph Model 46 41-51 (2013)
  11. Optimization of a screening lead for factor VIIa/TF. Young WB, Kolesnikov A, Rai R, Sprengeler PA, Leahy EM, Shrader WD, Sangalang J, Burgess-Henry J, Spencer J, Elrod K, Cregar L. Bioorg Med Chem Lett 11 2253-2256 (2001)
  12. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1. Gong L, Liu M, Zeng T, Shi X, Yuan C, Andreasen PA, Huang M. J Biol Chem 290 25795-25804 (2015)
  13. A structural mechanism of flavonoids in inhibiting serine proteases. Xue G, Gong L, Yuan C, Xu M, Wang X, Jiang L, Huang M. Food Funct 8 2437-2443 (2017)
  14. Protein S-thiolation by Glutathionylspermidine (Gsp): the role of Escherichia coli Gsp synthetASE/amidase in redox regulation. Chiang BY, Chen TC, Pai CH, Chou CC, Chen HH, Ko TP, Hsu WH, Chang CY, Wu WF, Wang AH, Lin CH. J Biol Chem 285 25345-25353 (2010)
  15. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors. Katz BA, Elrod K, Verner E, Mackman RL, Luong C, Shrader WD, Sendzik M, Spencer JR, Sprengeler PA, Kolesnikov A, Tai VW, Hui HC, Breitenbucher JG, Allen D, Janc JW. J Mol Biol 329 93-120 (2003)
  16. Exploring structurally conserved solvent sites in protein families. Bottoms CA, White TA, Tanner JJ. Proteins 64 404-421 (2006)
  17. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2. Huggins DJ. J Mol Graph Model 100 107710 (2020)
  18. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA). Katz BA, Luong C, Ho JD, Somoza JR, Gjerstad E, Tang J, Williams SR, Verner E, Mackman RL, Young WB, Sprengeler PA, Chan H, Mortara K, Janc JW, McGrath ME. J Mol Biol 344 527-547 (2004)
  19. Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability. Riggs JR, Kolesnikov A, Hendrix J, Young WB, Shrader WD, Vijaykumar D, Stephens R, Liu L, Pan L, Mordenti J, Green MJ, Sukbuntherng J. Bioorg Med Chem Lett 16 2224-2228 (2006)
  20. Atomic resolution structure of serine protease proteinase K at ambient temperature. Masuda T, Suzuki M, Inoue S, Song C, Nakane T, Nango E, Tanaka R, Tono K, Joti Y, Kameshima T, Hatsui T, Yabashi M, Mikami B, Nureki O, Numata K, Iwata S, Sugahara M. Sci Rep 7 45604 (2017)
  21. Comparative binding energy analysis for binding affinity and target selectivity prediction. Henrich S, Feierberg I, Wang T, Blomberg N, Wade RC. Proteins 78 135-153 (2010)
  22. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Mackman RL, Hui HC, Breitenbucher JG, Katz BA, Luong C, Martelli A, McGee D, Radika K, Sendzik M, Spencer JR, Sprengeler PA, Tario J, Verner E, Wang J. Bioorg Med Chem Lett 12 2019-2022 (2002)
  23. Binding free energy of protein/ligand complexes calculated using dissociation Parallel Cascade Selection Molecular Dynamics and Markov state model. Hata H, Phuoc Tran D, Marzouk Sobeh M, Kitao A. Biophys Physicobiol 18 305-316 (2021)
  24. 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Spencer JR, McGee D, Allen D, Katz BA, Luong C, Sendzik M, Squires N, Mackman RL. Bioorg Med Chem Lett 12 2023-2026 (2002)
  25. Evaluation of docking performance in a blinded virtual screening of fragment-like trypsin inhibitors. Surpateanu G, Iorga BI. J Comput Aided Mol Des 26 595-601 (2012)
  26. Factor VIIa inhibitors: gaining selectivity within the trypsin family. Shrader WD, Kolesnikov A, Burgess-Henry J, Rai R, Hendrix J, Hu H, Torkelson S, Ton T, Young WB, Katz BA, Yu C, Tang J, Cabuslay R, Sanford E, Janc JW, Sprengeler PA. Bioorg Med Chem Lett 16 1596-1600 (2006)
  27. Estimating the Roles of Protonation and Electronic Polarization in Absolute Binding Affinity Simulations. King E, Qi R, Li H, Luo R, Aitchison E. J Chem Theory Comput 17 2541-2555 (2021)
  28. Improving Small-Molecule Force Field Parameters in Ligand Binding Studies. Raniolo S, Limongelli V. Front Mol Biosci 8 760283 (2021)
  29. The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate. Zesławska E, Jacob U, Stürzebecher J, Oleksyn BJ. Bioorg Med Chem Lett 16 228-234 (2006)
  30. Design of a high fragment efficiency library by molecular graph theory. Venhorst J, Núñez S, Kruse CG. ACS Med Chem Lett 1 499-503 (2010)
  31. Exploration of conformational transition in the aryl-binding site of human FXa using molecular dynamics simulations. Wang JF, Hao P, Li YX, Dai JL, Li X. J Mol Model 18 2717-2725 (2012)
  32. Development of potent and selective factor Xa inhibitors. Rai R, Kolesnikov A, Li Y, Young WB, Leahy E, Sprengeler PA, Verner E, Shrader WD, Burgess-Henry J, Sangalang JC, Allen D, Chen X, Katz BA, Luong C, Elrod K, Cregar L. Bioorg Med Chem Lett 11 1797-1800 (2001)
  33. Trypsin-ligand binding free energy calculation with AMOEBA. Shi Y, Jiao D, Schnieders MJ, Ren P. Annu Int Conf IEEE Eng Med Biol Soc 2009 2328-2331 (2009)
  34. Efforts toward oral bioavailability in factor VIIa inhibitors. Vijaykumar D, Rai R, Shaghafi M, Ton T, Torkelson S, Leahy EM, Riggs JR, Hu H, Sprengeler PA, Shrader WD, O'Bryan C, Cabuslay R, Sanford E, Gjerstadt E, Liu L, Sukbuntherng J, Young WB. Bioorg Med Chem Lett 16 3829-3832 (2006)
  35. Screening of benzamidine-based thrombin inhibitors via a linear interaction energy in continuum electrostatics model. Nicolotti O, Giangreco I, Miscioscia TF, Convertino M, Leonetti F, Pisani L, Carotti A. J Comput Aided Mol Des 24 117-129 (2010)
  36. Small molecule inhibitors of plasma kallikrein. Young WB, Rai R, Shrader WD, Burgess-Henry J, Hu H, Elrod KC, Sprengeler PA, Katz BA, Sukbuntherng J, Mordenti J. Bioorg Med Chem Lett 16 2034-2036 (2006)
  37. Enrichment and Identification of the Most Abundant Zinc Binding Proteins in Developing Barley Grains by Zinc-IMAC Capture and Nano LC-MS/MS. Dionisio G, Uddin MN, Vincze E. Proteomes 6 E3 (2018)
  38. Thrombin inhibitors with novel P1 binding pocket functionality: free energy of binding analysis. Mlinsek G, Oblak M, Hodoscek M, Solmajer T. J Mol Model 13 247-254 (2007)
  39. Finding Lead Compounds for Dengue Antivirals from a Collection of Old Drugs through In Silico Target Prediction and Subsequent In Vitro Validation. Abdullah ZL, Chee HY, Yusof R, Mohd Fauzi F. ACS Omega 8 32483-32497 (2023)


Quick links